DSMB Recommends Continuing 60 Degrees’ Tafenoquine Trial for Chronic Babesiosis
DSMB recommends continuing 60 Degrees' tafenoquine trial for chronic babesiosis after safety review of interim data through Day 30.
Harvard’s COMPASS Model Just Made Immunotherapy Trial Design More Complicated
Harvard's COMPASS AI predicts checkpoint inhibitor response across 33 cancer types with 8.5% better accuracy—but translating that into trial...
400 Clinical Researchers Release AI Benchmarking Report for Trial Operations
400 clinical researchers release AI Benchmarking Report for trial operations, establishing industry baseline standards for sponsor and site adoption.
WCG Report: Only 11% of Pharma Firms Fully Implemented AI in Clinical Trials
Only 11% of pharma firms have fully implemented AI in clinical trials as of late 2024, according to WCG's...
Can-Fite’s Namodenoson Meets Safety Goal in Phase 2a Pancreatic Cancer Study
Can-Fite's namodenoson met safety goals in Phase 2a pancreatic cancer study, with third-line patients showing median survival exceeding five...
The PARTNERS Trial Is Running a Clinical Experiment That Has Never Been Done Before. The World Is Watching.
The PARTNERS trial opened BVD enrollment July 2, 2026, testing MBP134 and obeldesivir for a hemorrhagic fever that kills...
What a Single-Dose Synthetic Psychedelic Teaches Us About the Limits of Our TRD Trial Designs
A JAMA Psychiatry trial of inhaled mebufotenin in TRD shows rapid antidepressant response, and exposes critical gaps in how...
What Semaglutide’s Fentanyl Data Should Mean for How We Design the Next OUD Trial
New preclinical data shows semaglutide cuts fentanyl self-administration in rats, and raises hard questions about OUD trial design for...
Imviva Gets FDA Clearance for clonoSEQ in CTD402 T-ALL Trial
Imviva gains FDA clearance for clonoSEQ in CTD402 T-ALL trial, enabling MRD-driven patient management decisions in allogeneic CAR-T therapy...
Brii Bio’s ENRICH Study Shows 42.9% HBsAg Loss in Hepatitis B
Brii Bio's ENRICH study demonstrates 42.9% HBsAg loss in hepatitis B patients, but Phase 3 advancement faces legal constraints...